Role of non-classical MHC class I molecules in cancer immunosuppression

Growing neoplasms employ various mechanisms to evade immunosurveillance. The expression of non-classical MHC class I molecules by both immune and malignant cells in the tumor microenvironment constitute of the strategies used by tumors to circumvent the cytotoxic activity of effector cells of the immune system. The overexpression of HLA-G, -E, and -F is a common finding across a variety of malignancies. However, while the presence of HLA-G and HLA-E has been recently correlated with poor clinical outcome, information on the clinicopathological significance of HLA-F is limited. In the present review, we summarize studies on non-classical MHC class I molecules with special emphasis on their role in the modulation of anticancer immune responses.

[1]  N. Rouas-Freiss,et al.  Beyond the increasing complexity of the immunomodulatory HLA-G molecule. , 2008, Blood.

[2]  H. Orr,et al.  HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. , 1988, Journal of immunology.

[3]  Julia M. Lewis,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[4]  D. Geraghty,et al.  Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F, and G in Maternal-Placental Immune Recognition 1 , 2003, The Journal of Immunology.

[5]  A. Moreau,et al.  Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells1 , 2006, The Journal of Immunology.

[6]  A. Hayday,et al.  Regulation of cutaneous malignancy by gammadelta T cells. , 2001, Science.

[7]  S. Ferrone,et al.  Soluble HLA‐A,‐B,‐C and ‐G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation , 2003, European journal of immunology.

[8]  H. Rammensee,et al.  Nonclassical HLA-G molecules are classical peptide presenters , 1996, Current Biology.

[9]  P. Coulie,et al.  Identification of effector‐memory CMV‐specific T lymphocytes that kill CMV‐infected target cells in an HLA‐E‐restricted fashion , 2005, European journal of immunology.

[10]  J. Dausset,et al.  HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. , 2003, Advances in immunology.

[11]  A. McMichael,et al.  TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide , 1998, Current Biology.

[12]  H. Orr,et al.  Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. , 1990, Human immunology.

[13]  A. McMichael,et al.  The human major histocompatibility complex class Ib molecule HLA‐E binds signal sequence‐derived peptides with primary anchor residues at positions 2 and 9 , 1997, European journal of immunology.

[14]  E. Donadi,et al.  A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. , 2011, Molecular biology and evolution.

[15]  A. Merlo,et al.  Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. , 2000, Human immunology.

[16]  D. Geraghty,et al.  HLA‐F is a surface marker on activated lymphocytes , 2010, European journal of immunology.

[17]  J. Kellermann,et al.  Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding. , 1992 .

[18]  D. Geraghty,et al.  Analysis of HLA-E expression in human tumors , 2003, Immunogenetics.

[19]  M. Sarwal,et al.  Expression of Soluble HLA-G Identifies Favorable Outcomes in Liver Transplant Recipients , 2010, Transplantation.

[20]  E. Carosella,et al.  Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. , 2006, Transplant immunology.

[21]  J. Johnson,et al.  Analysis of HLA class Ib gene expression in male gametogenic cells , 1997, European journal of immunology.

[22]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[23]  M. Kurrer,et al.  Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. , 2001, The American journal of pathology.

[24]  J. Michálek,et al.  Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. , 2012, Pathology, research and practice.

[25]  A. McMichael,et al.  Requirement of the Proteasome for the Trimming of Signal Peptide-derived Epitopes Presented by the Nonclassical Major Histocompatibility Complex Class I Molecule HLA-E* , 2003, Journal of Biological Chemistry.

[26]  E. Donadi,et al.  Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. , 2008, Transplant immunology.

[27]  S. Ugurel,et al.  Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon‐α immunotherapy , 2001 .

[28]  K. Bogunia-Kubik,et al.  Clinical Significance of the HLA-E and CD94/NKG2 Interaction , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[29]  S. Ugurel,et al.  Soluble HLA‐DR is a potent predictive indicator of disease progression in serum from early‐stage melanoma patients , 2002, International journal of cancer.

[30]  J. Bell,et al.  Functional characterization of HLA‐F and binding of HLA‐F tetramers to ILT2 and ILT4 receptors , 2000, European journal of immunology.

[31]  M. Weller,et al.  HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells , 2012, Journal of Neuroimmunology.

[32]  X. Zhang,et al.  Alteration of HLA‐F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma , 2013, International journal of cancer.

[33]  D. Geraghty,et al.  Definitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data. , 2002, Tissue antigens.

[34]  J. Dausset,et al.  Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6—STAT3 signaling pathway , 2008, Proceedings of the National Academy of Sciences.

[35]  R. Rizzo,et al.  HLA-G expression is a fundamental prerequisite to pregnancy. , 2007, Human immunology.

[36]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[37]  Judith E. Cartwright,et al.  Soluble HLA-G and control of angiogenesis. , 2007, Journal of reproductive immunology.

[38]  E. Carosella,et al.  The immunosuppressive molecule HLA-G and its clinical implications , 2012, Critical reviews in clinical laboratory sciences.

[39]  L. Chess,et al.  Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. , 2001, Journal of immunology.

[40]  S. Munro,et al.  Selective Export of HLA-F by Its Cytoplasmic Tail1 , 2006, The Journal of Immunology.

[41]  E. Jordanova,et al.  HLA-E expression in cervical adenocarcinomas: association with improved long-term survival , 2012, Journal of Translational Medicine.

[42]  H. Orr,et al.  A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Volteau,et al.  HLA‐E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression , 2012, International journal of cancer.

[44]  Kouhei Tsumoto,et al.  Efficient Leukocyte Ig-like Receptor Signaling and Crystal Structure of Disulfide-linked HLA-G Dimer* , 2006, Journal of Biological Chemistry.

[45]  N. Rouas-Freiss,et al.  Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology. , 2005, Autoimmunity reviews.

[46]  D. Chan,et al.  HLA-G is a potential tumor marker in malignant ascites. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  A. Berrebi,et al.  HLA class I/NK cell receptor interaction in early human decidua basalis: possible functional consequences. , 2005, Chemical immunology and allergy.

[48]  V. Guiard,et al.  © 1999 The Japanese Society for Immunology IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes , 2022 .

[49]  H. Orr,et al.  Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element , 1990, The Journal of experimental medicine.

[50]  Elisa Lo Monaco,et al.  High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis , 2011, Journal of Translational Medicine.

[51]  L. Chess,et al.  Induction of TCR Vβ-Specific CD8+ CTLs by TCR Vβ-Derived Peptides Bound to HLA-E1 , 2001, The Journal of Immunology.

[52]  E. Carosella,et al.  HLA‐G up‐regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  K. Egawa,et al.  Detection of anti-HLA-F antibodies in sera from cancer patients. , 2004, Anticancer research.

[54]  L. Chess,et al.  HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. , 2010, The Journal of clinical investigation.

[55]  Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding , 2013, Molecular and Cellular Biochemistry.

[56]  Judith E. Cartwright,et al.  Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. , 2006, Blood.

[57]  N. Rouas-Freiss,et al.  Modulation of HLA-G Expression in Human Neural Cells after Neurotropic Viral Infections , 2005, Journal of Virology.

[58]  Wei Zhang,et al.  Tolerization of dendritic cells by HLA‐G , 2005, European journal of immunology.

[59]  B. Seliger,et al.  Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. , 2003, Human immunology.

[60]  Shiyong Chen,et al.  Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. , 2009, The Journal of infectious diseases.

[61]  A. Moreau,et al.  Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. , 2007, Blood.

[62]  J. Johnson,et al.  Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding , 1992, The Journal of experimental medicine.

[63]  S. H. van der Burg,et al.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes , 2011, Proceedings of the National Academy of Sciences.

[64]  C. Demanet,et al.  Soluble HLA-G in rheumatoid arthritis. , 2006, Human immunology.

[65]  K. Thielemans,et al.  Lentiviral vectors: a versatile tool to fight cancer. , 2013, Current molecular medicine.

[66]  A. Woltman,et al.  Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. , 1999, Journal of immunology.

[67]  L. Lanier,et al.  A Signal Peptide Derived from hsp60 Binds HLA-E and Interferes with CD94/NKG2A Recognition , 2002, The Journal of experimental medicine.

[68]  S. Ferrone,et al.  HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? , 2005, Cancer research.

[69]  D. Geraghty,et al.  HLA-F Surface Expression on B Cell and Monocyte Cell Lines Is Partially Independent from Tapasin and Completely Independent from TAP1 , 2003, The Journal of Immunology.

[70]  E. Carosella,et al.  Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. , 2006, Blood.

[71]  P. Moreau,et al.  Trogocytosis‐based generation of suppressive NK cells , 2007, The EMBO journal.

[72]  S. Agaugué,et al.  Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. , 2011, Blood.

[73]  D. Furman,et al.  Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. , 2008, International journal of oncology.

[74]  J. Dausset,et al.  Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Wenfu Zhou,et al.  HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. , 2011, Lung cancer.

[76]  J. McCluskey,et al.  Biology and functions of human leukocyte antigen-G in health and sickness. , 2003, Tissue antigens.

[77]  O. Mandelboim,et al.  Soluble nonclassical HLA generated by the metalloproteinase pathway. , 2003, Human immunology.

[78]  G. Ferrara,et al.  HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. , 2000, Human immunology.

[79]  Kazuhiro Suzuki,et al.  The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA‐E through mostly shared but partly distinct sets of HLA‐E residues , 2004, European journal of immunology.

[80]  P. J. van den Elsen,et al.  Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. , 2000, Human immunology.

[81]  D. Stolke,et al.  Secretion of sHLA-G molecules in malignancies. , 2003, Seminars in cancer biology.

[82]  P. A. Peterson,et al.  Cell surface expression of HLA‐E: interaction with human β2‐microglobulin and allelic differences , 1999, European journal of immunology.

[83]  M. Weller,et al.  HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. , 2005, Journal of neuropathology and experimental neurology.

[84]  P. Le Bouteiller,et al.  Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story. , 1996, Research in immunology.

[85]  Longmei Zhao,et al.  Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization. , 2012, Human immunology.

[86]  B. Dréno,et al.  Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer , 2011, PloS one.

[87]  J. Dausset,et al.  HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.